Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

392
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
392
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.0K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic changes in mean corpuscular volume could be integrated into longitudinal prediction frameworks for individualized risk assessment in the ICU setting: A retrospective study.

Science progress·2026
Same author

CD11c<sup>+</sup> Cells Control Platelet Homeostasis in a Murine Bone Marrow Chimeric Atherosclerosis Model.

Biomedicines·2026
Same author

The complement-dendritic cell-endothelial cell crosstalk in vascular inflammation.

Cardiovascular research·2025
Same author

Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure.

European heart journal·2025
Same author

Cystine import and oxidative catabolism fuel vascular growth and repair via nutrient-responsive histone acetylation.

Cell metabolism·2025
Same author

Prognostic impact of rheumatic diseases in patients with heart failure with mildly reduced ejection fraction.

Clinical research in cardiology : official journal of the German Cardiac Society·2025

Related Experiment Video

Updated: Feb 23, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K

Immune mechanisms in heart failure.

Yingying Zhang1,2,3, Johann Bauersachs4, Harald F Langer1,2

  • 1University Hospital, Department of Cardiology and Cardiovascular Medicine, Eberhard Karls University Tuebingen, Tuebingen, Germany.

European Journal of Heart Failure
|September 12, 2017
PubMed
Summary

Inflammation plays a key role in heart failure (HF) progression, impacting cardiac remodelling. Targeting immune responses in HF has yielded surprising and often negative results, necessitating further research into therapeutic strategies.

Keywords:
Antigen presenting cellsHeart failureImmune responseInflammation

More Related Videos

Isolation of Functional Cardiac Immune Cells
07:26

Isolation of Functional Cardiac Immune Cells

Published on: December 5, 2011

15.6K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.9K

Related Experiment Videos

Last Updated: Feb 23, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K
Isolation of Functional Cardiac Immune Cells
07:26

Isolation of Functional Cardiac Immune Cells

Published on: December 5, 2011

15.6K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.9K

Area of Science:

  • Cardiology
  • Immunology
  • Translational Medicine

Background:

  • Elevated pro-inflammatory biomarkers are linked to heart failure (HF) severity and prognosis in both ischemic and non-ischemic cases.
  • Immune response activation within the heart contributes to adverse cardiac remodeling and left ventricular dysfunction.

Purpose of the Study:

  • To review immune mediators in HF pathogenesis and progression.
  • To explore therapeutic applications targeting inflammation in HF.
  • To highlight the role of immune activation in various HF origins, including valvular heart disease and volume overload.

Main Methods:

  • Literature review of experimental and clinical studies on inflammation in heart failure.
  • Analysis of immune mediators and their role in cardiac remodeling.
  • Discussion of clinical trial outcomes targeting immune pathways in HF.

Main Results:

  • Clinical trials targeting immune effectors in HF have shown neutral or detrimental effects, sometimes worsening HF outcomes.
  • Immune activation is relevant across diverse HF etiologies, not limited to inflammatory or ischemic cardiomyopathies.

Conclusions:

  • Understanding the intricate interplay between immune mechanisms and cardiac remodeling in HF is crucial.
  • Identifying cell-specific and molecular targets within the immune response may lead to novel biomarkers and therapeutic strategies for HF.